Human CD20 (Research Grade Tositumomab Biosimilar) Alexa Fluor™ Plus 405-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB10440AFP405
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, CyTOF-ready
Label
Alexa Fluor Plus 405 (Excitation = 404 nm, Emission = 455 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Hu11A
Product Specifications
Specificity
Detects Human CD20 based on Tositumomab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Tositumomab. This product is for research use only.
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications
Application
Recommended Usage
CyTOF-ready
Optimal dilution of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilution of this antibody should be experimentally determined.
Background: CD20
Long Name
Cluster of Differentiation 20
Alternate Names
B1, Bp35, CD20, LEU-16, Ly-44, MS4A1, S7
Entrez Gene IDs
Gene Symbol
MS4A1
Additional CD20 Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...